NBI-98854 + NBI-98854 + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tardive Dyskinesia
Conditions
Tardive Dyskinesia
Trial Timeline
Aug 1, 2011 → Feb 1, 2012
NCT ID
NCT01393600About NBI-98854 + NBI-98854 + Placebo
NBI-98854 + NBI-98854 + Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT01393600. Target conditions include Tardive Dyskinesia.
What happened to similar drugs?
3 of 7 similar drugs in Tardive Dyskinesia were approved
Approved (3) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01733121 | Phase 2 | Completed |
| NCT01688037 | Phase 2 | Completed |
| NCT01393600 | Phase 2 | Completed |
Competing Products
13 competing products in Tardive Dyskinesia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sarizotan | Merck | Pre-clinical | 18 |
| levetiracetam + placebo | UCB | Phase 3 | 40 |
| Valbenazine | Neurocrine Biosciences | Phase 1 | 18 |
| Valbenazine Oral Capsule | Neurocrine Biosciences | Approved | 32 |
| NBI-98854 + NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 32 |
| NBI-98854 | Neurocrine Biosciences | Phase 3 | 37 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Approved | 40 |
| NBI-98854 | Neurocrine Biosciences | Phase 2 | 32 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 3 | 37 |
| Valbenazine | Neurocrine Biosciences | Phase 3 | 37 |
| NBI-98854 + NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 32 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Approved | 40 |
| NBI-1065890 + Placebo | Neurocrine Biosciences | Phase 2 | 39 |